Endocrine-sensitive disease rate in postmenopausal patients with estrogen receptor-rich/ERBB2-negative breast cancer receiving neoadjuvant anastrozole, fulvestrant, or their combination: A phase 3 randomized clinical trial

Authors

Cynthia X Ma, Washington University School of Medicine in St. Louis
Kiran Vij, Washington University School of Medicine in St. Louis
Jeremy Hoog, Washington University School of Medicine in St. Louis
Mark A Watson, Washington University School of Medicine in St. Louis
Erika Crouch, Washington University School of Medicine in St. Louis
et al.

Journal

JAMA Oncology

Publication Date

3-1-2024

Volume

10

Issue

3

First Page

362

Last Page

371

Document Type

Open Access Publication

DOI

10.1001/jamaoncol.2023.6038

Rights and Permissions

Ma CX, Suman VJ, Sanati S, et al. Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024;10(3):362–371. doi:10.1001/jamaoncol.2023.6038. This is an open access article distributed under the terms of the CC-BY License. © 2024 Ma CX et al. JAMA Oncology.

Recommended Citation

Ma, Cynthia X; Vij, Kiran; Hoog, Jeremy; Watson, Mark A; Crouch, Erika; and et al., "Endocrine-sensitive disease rate in postmenopausal patients with estrogen receptor-rich/ERBB2-negative breast cancer receiving neoadjuvant anastrozole, fulvestrant, or their combination: A phase 3 randomized clinical trial." JAMA Oncology. 10, 3. 362 - 371. (2024).
https://digitalcommons.wustl.edu/oa_4/4711

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.